VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SECZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025.
BioMedNewsBreaks — VERAXA Biotech AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”) Announce $1.64 Billion Business Combination to Create Clinical-Stage Cancer Therapy PowerhouseVERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (
NASDAQ: VACH) announced a definitive agreement to merge in a transaction that would value the combined company at approximately $1.64 billion. Upon closing, VERAXA is expected to trade on NASDAQ under the ticker symbol “VERX.” The company is advancing a proprietary Bi-Targeted Antibody Cytotoxicity (“BiTAC”) platform for dual-marker cancer therapeutics, including bispecific ADCs and T cell engagers, with a pipeline featuring nine programs and an active Phase 1 trial in leukemia. VERAXA is backed by majority shareholders Xlife Sciences AG (SIX: XLS), EMBL and EMBLEM, and led by CEO Christoph Antz, Ph.D., and CBO Heinz Schwer, Ph.D., MBA. Voyager expects to provide up to $253 million in cash from its trust account to fund operations, while VERAXA is pursuing a crossover round expected to close before the deal’s completion, targeted for Q4 2025.
VERAXA Biotech Appoints Rick Austin as Chief Scientific OfficerIndustry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies
